SpyGlass Pharma, Inc. Common Stock (SGP) Investor Relations Documents

SpyGlass Pharma, Inc. Common Stock (SGP) investor relations documents from the company's IR site: 1 presentation, 13 press releases; latest deck 2026-08-01. Read in-app with summaries. First-party data.

August 2026 Corporate Presentation — SpyGlass Pharma is developing the Bimatoprost Drug Pad-IOL System to treat glaucoma during cataract surgery, targeting a $13 billion U.S. addressable market.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-06Press releaseSpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
2026-08-01PresentationAugust 2026 Corporate Presentation
2026-06-15Press releaseSpyGlass Pharma Appoints Shannon Treviño as General Counsel
2026-06-02Press releaseSpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing
2026-05-21Press releaseSpyGlass Pharma to Participate in Upcoming Investor Conferences
2026-05-18Press releaseSpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL System
2026-05-14Press releaseSpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
2026-03-26Press releaseSpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update
2026-03-09Press releaseSpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System
2026-03-04Press releaseSpyGlass Pharma to Participate in the Jefferies Biotech on the Beach Summit
2026-02-09Press releaseSpyGlass Pharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchas
2026-01-20Press releaseSpyGlass Pharma Announces First Patients Randomized in SGP-005 and SGP-006, Two Registrational Phase III Clinical Trials
2025-04-24Press releasePDF Version
2024-10-17Press releasePDF Version

SGP overview · SGP earnings · SGP financials · SGP KPIs · SGP ownership · SGP peers · SGP filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.